Jennifer C Lai1, Jennifer L Dodge, Matthew R Kappus, Randi Wong, Yara Mohamad, Dorry L Segev, Mara McAdams-DeMarco. 1. 1Department of Medicine, University of California-San Francisco, San Francisco, California, USA; 2Division of Gastroenterology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA; 3Department of Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland, USA; 4Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Abstract
INTRODUCTION: We developed the strength training intervention (STRIVE), a home-based exercise program targeting physical function in patients with cirrhosis. In this pilot study, we aimed to evaluate the safety and efficacy of STRIVE. METHODS: Eligible were adult patients with cirrhosis at 3 sites. Patients were randomized 2:1-12 weeks of STRIVE, a 30-minute strength training video plus a health coach or standard of care (SOC). Physical function and quality of life were assessed using the Liver Frailty Index (LFI) and Chronic Liver Disease Questionnaire (CLDQ), respectively. RESULTS: Fifty-eight and 25 were randomized to STRIVE and SOC arms, respectively: 43% women, median age was 61 years, MELDNa, Model for End-Stage Liver Disease Sodium was 14, and 54% were Child-Pugh B/C. Baseline characteristics were similar in the STRIVE vs SOC arms except for rates of hepatic encephalopathy (19 vs 36%). LFI @ 12 weeks was available in 43 STRIVE and 20 SOC participants. After 12 weeks, the median LFI improved from 3.8 to 3.6 (ΔLFI -0.1) in the STRIVE arm and 3.7 to 3.6 (ΔLFI -0.1) in the SOC arm (P = 0.65 for ΔLFI difference). CLDQ scores improved from 4.6 to 5.2 in STRIVE participants (ΔCLDQ 0.38) and did not change in SOC participants (4.2-4.2; ΔCLDQ -0.03) (P = 0.09 for ΔCLDQ difference). One patient died (SOC arm) of bleeding. Only 14% of STRIVE participants adhered to the strength training video for 10-12 weeks. No adverse events were reported by STRIVE participants. DISCUSSION: STRIVE, a home-based structured exercise program for patients with cirrhosis, was safely administered at 3 sites, but adherence was low. Although all participants showed minimal improvement in the LFI, STRIVE was associated with a substantial improvement in quality of life.
INTRODUCTION: We developed the strength training intervention (STRIVE), a home-based exercise program targeting physical function in patients with cirrhosis. In this pilot study, we aimed to evaluate the safety and efficacy of STRIVE. METHODS: Eligible were adult patients with cirrhosis at 3 sites. Patients were randomized 2:1-12 weeks of STRIVE, a 30-minute strength training video plus a health coach or standard of care (SOC). Physical function and quality of life were assessed using the Liver Frailty Index (LFI) and Chronic Liver Disease Questionnaire (CLDQ), respectively. RESULTS: Fifty-eight and 25 were randomized to STRIVE and SOC arms, respectively: 43% women, median age was 61 years, MELDNa, Model for End-Stage Liver Disease Sodium was 14, and 54% were Child-Pugh B/C. Baseline characteristics were similar in the STRIVE vs SOC arms except for rates of hepatic encephalopathy (19 vs 36%). LFI @ 12 weeks was available in 43 STRIVE and 20 SOC participants. After 12 weeks, the median LFI improved from 3.8 to 3.6 (ΔLFI -0.1) in the STRIVE arm and 3.7 to 3.6 (ΔLFI -0.1) in the SOC arm (P = 0.65 for ΔLFI difference). CLDQ scores improved from 4.6 to 5.2 in STRIVE participants (ΔCLDQ 0.38) and did not change in SOC participants (4.2-4.2; ΔCLDQ -0.03) (P = 0.09 for ΔCLDQ difference). One patient died (SOC arm) of bleeding. Only 14% of STRIVE participants adhered to the strength training video for 10-12 weeks. No adverse events were reported by STRIVE participants. DISCUSSION: STRIVE, a home-based structured exercise program for patients with cirrhosis, was safely administered at 3 sites, but adherence was low. Although all participants showed minimal improvement in the LFI, STRIVE was associated with a substantial improvement in quality of life.
Authors: Jennifer C Lai; Kenneth E Covinsky; Jennifer L Dodge; W John Boscardin; Dorry L Segev; John P Roberts; Sandy Feng Journal: Hepatology Date: 2017-06-28 Impact factor: 17.425
Authors: David M Chascsa; Jennifer C Lai; Michael A Dunn; Aldo J Montano-Loza; Matthew R Kappus; Srinivasan Dasarathy; Elizabeth J Carey Journal: Dig Dis Sci Date: 2018-09-03 Impact factor: 3.199
Authors: Annalisa Berzigotti; Agustín Albillos; Candid Villanueva; Joan Genescá; Alba Ardevol; Salvador Augustín; Jose Luis Calleja; Rafael Bañares; Juan Carlos García-Pagán; Francisco Mesonero; Jaime Bosch Journal: Hepatology Date: 2017-03-06 Impact factor: 17.425
Authors: Jennifer C Lai; Jennifer L Dodge; Matthew R Kappus; Michael A Dunn; Michael L Volk; Andres Duarte-Rojo; Daniel R Ganger; Robert S Rahimi; Charles E McCulloch; Christine E Haugen; Mara McAdams-DeMarco; Daniela P Ladner; Dorry L Segev; Elizabeth C Verna Journal: J Hepatol Date: 2020-03-30 Impact factor: 25.083
Authors: Nancy K Latham; Bette Ann Harris; Jonathan F Bean; Timothy Heeren; Christine Goodyear; Stacey Zawacki; Diane M Heislein; Jabed Mustafa; Poonam Pardasaney; Marie Giorgetti; Nicole Holt; Lori Goehring; Alan M Jette Journal: JAMA Date: 2014-02-19 Impact factor: 56.272
Authors: Jennifer C Lai; Dorry L Segev; Charles E McCulloch; Kenneth E Covinsky; Jennifer L Dodge; Sandy Feng Journal: Am J Transplant Date: 2018-03-13 Impact factor: 8.086
Authors: Jennifer C Lai; Puneeta Tandon; William Bernal; Elliot B Tapper; Udeme Ekong; Srinivasan Dasarathy; Elizabeth J Carey Journal: Hepatology Date: 2021-09 Impact factor: 17.298